Characterization of the myocardial and renal renin-angiotensin system in normal cats and cats with hypertrophic cardiomyopathy. [PDF]
Wood JE +6 more
europepmc +1 more source
The effectiveness and safety of sacubitril/valsartan in real-world dialysis patients with heart failure reduced ejection fraction. [PDF]
Tu KC, Weng YC, Liao CT, Wu JY.
europepmc +1 more source
Cardiac biomarkers response under angiotensin receptor-neprilysin inhibitor: a sub-analysis of the NATRIUM-HF study. [PDF]
Bruno J +15 more
europepmc +1 more source
In Vivo Inhibition of Dipeptidyl Peptidase 4 and Neprilysin Activity Enables Measurement of GLP-1 Secretion in Male Rats. [PDF]
Galsgaard KD +4 more
europepmc +1 more source
Pharmacophore-Based Identification and Molecular Characterization of Potent Neprilysin Inhibitors: Biochemical and Therapeutic Implications for Cardiovascular Diseases. [PDF]
Kuo CT, Wu YC, Li JM, Ju TC, Tseng TS.
europepmc +1 more source
Bleeding Disorder, A Newly Recognized Adverse Event Following Sacubitril/Valsartan Therapy. [PDF]
Al-Omari YW +3 more
europepmc +1 more source
Retraction: The angiotensin receptor neprilysin inhibitor LCZ696 attenuates renal fibrosis via ASK1/JNK/p38 MAPK-mediated apoptosis in unilateral ureteral obstruction. [PDF]
PLOS One Editors.
europepmc +1 more source
Short-term renal and cardiac outcomes of combined ARNI and SGLT2 therapy in AHF patients: a prospective single-arm interventional study. [PDF]
Zhang M, Huang Z, Wang C, Xu Y.
europepmc +1 more source
Japanese Nationwide Survey of New Heart Failure Drug Prescriptions by Pediatric Cardiologists. [PDF]
Muneuchi J, Collaborators.
europepmc +1 more source
The effects of sacubitril/valsartan compared to valsartan in experimentally induced chronic kidney disease. [PDF]
Al Maskari R +4 more
europepmc +1 more source

